About FCD
Faculty from the University of the Western Cape, Karolinska Institutet, the university that awards the Nobel Prize in medicine, and Harvard Business School formed FCD in 2016 to deliver the ‘right programs to the right learners at the right time’.
Our mission is to bring high quality science education to all, and to achieve this we share the knowledge, skills and experience of world leading experts with students who would not have access to similar university programs due to geographic, financial or time constraints.
FCD have trained participants from over 130 countries in collaboration with the Global Health Clinical Consortium, which includes product development partners such as IAVI, MMV, AAHI, DNDi, FIND, PATH, TB Alliance, IVI as well as Clinical Research Organizations including IQVIA, DFNET Research, FHI Clinical, Emmes and TCD-Global.
Since 2016 we have worked with the following organisations on education and capacity building programs TDR-WHO, The Global Health Network, Chan Sooon-Shiong Family Foundation-South African Medical Research Council Capacity Development Program, University of Oxford, Strathmore University, Kenya, CDT-Africa, University of the Western Cape, South Africa, Technological University of Dublin, King’s College London and University of Siena.
As partners of the Global Health Clinical Consortium FCD and CDT-Africa, Addis Ababa University successfully completed the transfer of the Clinical Research Operations program, which continues to train researchers on best practices in clinical trial management across the Continent.
FCD was recently selected by the Deutsche Gesellschaft für Internationale Zusammenarbeit (GIZ) GmbH, in collaboration with the Partnerships for African Vaccine Manufacturing, to help enable emerging African biomanufacturing training initiatives find the right operational and business model to develop biomanufacturing training centers in Africa.
Researchers at FCD are working with our partners to build a compelling business case for vaccine manufacturing on the Continent of Africa. This is in response to recent challenges encountered by Africa CDC’s goal to enable the African vaccine manufacturing industry produce 60% of its vaccine requirements by 2040.
